<DOC>
	<DOCNO>NCT01274325</DOCNO>
	<brief_summary>The purpose study test hypothesis Sereflo ( ICS/LABA ) could reduce airway inflammation asthmatic patient Seretide .</brief_summary>
	<brief_title>Comparison Anti-inflammatory Effects Seroflo Seretide Patients With Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<criteria>Age 2080 year Patients asthma diagnose accord American Thoracic Society criteria A baseline FEV1 &gt; = 50 % predicted reversibility FEV1 therapy inhale salbuterol ( 2.5 mg ) FEV1 12 % provocative concentration methacholine cause 20 % fall FEV1 ( PC20 ) &lt; = 8 mg/mL Prescribed use inhale corticosteroid ( brand ) least 12 week prior study entry The daily prescribed dose inhaled corticosteroid last 4 week prior study entry constant least 250 μg/day fluticasone least 400 μg/day budesonide least 500 μg/day beclomethasone Be able provide write informed consent Any asthma exacerbation respiratory tract infection affect asthma within 4 week prior randomization visit Intake oral , parenteral corticosteroid within 4 week and/or depot parenteral corticosteroid within 12 week prior randomization visit Current previous smoker smoke history &gt; = 10 pack year Previous randomization treatment present study Known suspect hypersensitivity study therapy Use βblocking agent , include eyedrops Pregnancy , breastfeed plan pregnancy study . Fertile woman use acceptable contraceptive pill measure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>asthma</keyword>
</DOC>